nach oben

Pituitary

Erschienen in:

01.06.2007

Defining normalcy of the somatotropic axis: an attainable goal?

verfasst von: Ariel L. Barkan

Erschienen in: Pituitary | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

The diagnoses of acromegaly and dwarfism require biochemical confirmation of abnormal GH and IGF-1 concentrations. The same parameters are used for therapeutic decisions, i.e. initiation or termination of particular treatments. Therefore, reliable and epidemiologically and statistically proven criteria of normalcy for GH and IGF-1 are required for these tasks to be accomplished. Despite major progress in all these areas, the definition of what constitutes “normalcy” of the somatotropic axis is still lacking. Using an example of acromegaly, we discuss the contradictions and the uncertainties of the biochemical diagnosis of this disease.

Glick AM, Roth J, Yalow RS, Berson SA (1963) Immunoassay of human growth hormone in plasma. Nature 199:784–787PubMedCrossRef

Ho PJ, Friberg RD, Barkan AL (1992) Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly. J Clin Endocrinol Metab 75(3):812–819PubMedCrossRef

Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkan AL (1994) Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 78(6):1403–1410PubMedCrossRef

Granada ML, Sanmarti A, Lucas A, Salinas I, Carrascosa A, Foz M, Audi L (1990) Assay-dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children. Acta Paediatr Scand Suppl 379:63–70; discussion 71

Christy NP (1982) Choosing the best treatment for acromegaly. JAMA 247(9):1320PubMedCrossRef

Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA (1993) Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg 78(2):205–215PubMedCrossRef

Bates AS, Van’t Hoff W, Jones JM, Clayton RN (1993) An audit of outcomes of treatment in acromegaly. Q J Med 86(5):293–299PubMed

Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41(1):95–102

Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29–41PubMedCrossRef

10.

Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674PubMedCrossRef

11.

Barreca A, Ciccarelli E, Minuto R, Bruzzi P, Giordano G, Camanni F (1989) Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol (Copenh) 120(5):629–635

12.

Barkan AL, Beitins IZ, Kelch RP (1998) Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 67(1):69–73

13.

Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA (2006) Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91(4):1239–1245PubMedCrossRef

14.

Barkan AL (2003) Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf) 58(2):132–135CrossRef

15.

Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WL, Barkan AL (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87(8):3537–3542PubMedCrossRef

16.

Desailloud R, Crepin-Hemon S, Simovic-Corroyer B (2005) Acromegaly in elderly people. Ann Endocrinol (Paris) 66(6):540–544

17.

Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD (2004) Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89(2):495–500PubMedCrossRef

18.

Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC (2002) Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 87(7):3142–3147PubMedCrossRef

19.

Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr D (2003) Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 52(2):181–185PubMedCrossRef

20.

Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, Arosio M (2005) Long-term evaluation of postoperative acromegalic patients in remission with pervious and newly proposed criteria. J Clin Endocrinol Metab 90(3):1377–1382PubMedCrossRef

21.

Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419–3426PubMedCrossRef

22.

Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after Transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58(1):86–91CrossRef

23.

Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW (2003) Long-term treatment outcome in acromegaly. Growth Horm IGF Res 13(4):185–192PubMedCrossRef

24.

Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE (1979) Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301(21):1138–1142PubMedCrossRef

25.

Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJC, Waters MJ (1998) A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-i and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 83:2554–2561PubMedCrossRef

26.

Barkan AL, Beitins IZ, Kelch RP (1988) Plasma insulin-like growth factor-1/somatomedin in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol. Metab 67:69–73PubMedCrossRef

27.

Freda PU (2003) Pitfalls in the biochemical assessment of acromegaly. Pituitary 6(3):135–140PubMedCrossRef

28.

Ho KK, O’Sullivan AJ, Wolthers T, Leung KC (2003) Metabolic effects of oestrogens: impact of the route of administration. Ann Endocrinol (Paris) 64(2):170–7

29.

Yakar S, Pennisi P, Wu Y, Zhao H, LeRoith D (2005) Clinical relevance of systemic and local IGF-1. Endocr Dev 9:11–16PubMedCrossRef

30.

Isgaard J, Carlsson L, Isaksson OG, Jansson JO. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion

31.

Bonapart IE, van Domburg R, ten Have SM, de Herder WW, Erdman RA, Janssen JA, van der Lely AJ (2005) The “bio-assay” quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-1 concentrations. Eur J Endocrinol 152(2):217–224PubMedCrossRef

Titel: Defining normalcy of the somatotropic axis: an attainable goal?
verfasst von: Ariel L. Barkan
Publikationsdatum: 01.06.2007
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Pituitary / Ausgabe 2/2007
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-007-0029-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Serum IGF-I levels in the diagnosis and monitoring of acromegaly

Growth hormone measurements in the diagnosis and monitoring of acromegaly

IGF-I measurements in the diagnosis of adult growth hormone deficiency

Introduction to the special issue of pituitary: “Utility of growth hormone and IGF-I assays”

Approach to the evaluation of the GH/IGF-axis in patients with pituitary disease: which test to order